Therapy escalation following an elevated HbA1c in adults aged 45 years and older living with diabetes in Australia: a real-world observational analysis
Version 2 2020-09-14, 18:31Version 2 2020-09-14, 18:31
Version 1 2020-09-14, 18:30Version 1 2020-09-14, 18:30
figure
posted on 2020-09-14, 18:31authored byYing Xie, Jannah Baker, Tamara Young, Min Jun, Louisa Sukkar, Anna Campain, Amy Kang, Alan Cass, Ji Hu, David Peiris, Carol Pollock, Germaine Wong, Sophia Zoungas, Kris Rogers, Meg Jardine, Carinna Hockham, the EXTEND45 Steering Committee
Stepwise escalation of glucose-lowering therapy to more intensive
regimens is an integral component of type 2 diabetes management (1). Early blood glucose control is associated with beneficial
effects on long-term micro- and macrovascular outcomes (2). Understanding factors associated with time to therapy escalation
following an elevated glycated hemoglobin (HbA1c) may inform interventions
to facilitate timely control. We used linked real-world data to examine time to therapy escalation following a
recorded HbA1c ≥8.0% (64 mmol/mol) and associated factors.
Funding
National Natural Science Foundation of China 81670742 Suzhou Municipal Science and Technology Bureau szxk201804